Literature DB >> 24275708

Native liver histology after successful portoenterostomy in biliary atresia.

Hanna Lampela1, Silja Kosola, Päivi Heikkilä, Jouko Lohi, Hannu Jalanko, Mikko P Pakarinen.   

Abstract

BACKGROUND: Biliary atresia is the most common indication for childhood liver transplantation. The effects of successful portoenterostomy (PE) on native liver histology remain unclear. AIMS: We assessed changes in native liver histology after a successful PE in relation to liver function and clinical outcomes.
METHODS: In total, 70 native liver biopsies of 44 biliary atresia patients were obtained at PE (n=30), 4.2 years after successful PE (n=23) and 1.1 years after failed PE (n=17), and reviewed for cholestasis, fibrosis, inflammation, and cytokeratin 7 (CK7) immunopositivity (chronic cholestasis). Ten transplant donor livers served as controls.
RESULTS: After a successful PE [serum bilirubin 11 (2 to 35) μmol/L at biopsy], histologic native liver cholestasis completely resolved in 83% of the patients and portal inflammation significantly decreased. Nevertheless, enhanced fibrosis [Metavir stage 2 (1-4) vs. 4 (1-4)], bile duct proliferation [grade 2 (1-2) vs. 1 (0-2)], and periportal CK7 immunostaining [grade 1 (0-2) vs. 1 (0-4)] persisted in 100%, 87%, and 61% of subjects, respectively. Metavir fibrosis stage corresponded cirrhosis (stage 4) in 52% of the patients, associated with the presence of portal hypertension, and correlated with serum-conjugated bilirubin (r=0.601, P=0.002), bile duct proliferation (r=0.657, P=0.001), and CK7 positivity (r=0.657, P=0.001). Aspartate transferase to platelet ratio index predicted native liver fibrosis and development of esophageal varices. The degree of fibrosis and portal inflammation at PE were unrelated to native liver survival.
CONCLUSIONS: Despite resolution of cholestasis and decreasing inflammation, bile duct proliferation, periportal CK7 immunostaining, and fibrosis persist after successful PE. Fibrosis is associated with biochemical cholestasis, bile duct proliferation, CK7 immunopositivity (chronic cholestasis), and development of portal hypertension.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24275708     DOI: 10.1097/MCG.0000000000000013

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  18 in total

1.  Prognostic factors indicating survival with native liver after Kasai procedure for biliary atresia.

Authors:  Juma Obayashi; Kohei Kawaguchi; Shutaro Manabe; Hideki Nagae; Munechika Wakisaka; Junki Koike; Masayuki Takagi; Hiroaki Kitagawa
Journal:  Pediatr Surg Int       Date:  2017-08-29       Impact factor: 1.827

2.  Key Histopathologic Features of Liver Biopsies That Distinguish Biliary Atresia From Other Causes of Infantile Cholestasis and Their Correlation With Outcome: A Multicenter Study.

Authors:  Pierre Russo; John C Magee; Robert A Anders; Kevin E Bove; Catherine Chung; Oscar W Cummings; Milton J Finegold; Laura S Finn; Grace E Kim; Mark A Lovell; Margret S Magid; Hector Melin-Aldana; Sarangarajan Ranganathan; Bahig M Shehata; Larry L Wang; Frances V White; Zhen Chen; Catherine Spino
Journal:  Am J Surg Pathol       Date:  2016-12       Impact factor: 6.394

3.  Diagnosing native liver fibrosis and esophageal varices using liver and spleen stiffness measurements in biliary atresia: a pilot study.

Authors:  Hirofumi Tomita; Kiyoshi Ohkuma; Yohei Masugi; Naoki Hosoe; Ken Hoshino; Yasushi Fuchimoto; Akihiro Fujino; Takahiro Shimizu; Mototoshi Kato; Takumi Fujimura; Hideo Ishihama; Nobuhiro Takahashi; Yutaka Tanami; Hirotoshi Ebinuma; Hidetsugu Saito; Michiie Sakamoto; Miwako Nakano; Tatsuo Kuroda
Journal:  Pediatr Radiol       Date:  2016-06-14

4.  The combination of conventional ultrasound and shear-wave elastography in evaluating the segmental heterogeneity of liver fibrosis in biliary atresia patients after Kasai portoenterostomy.

Authors:  Wenying Zhou; Xiaoju Li; Nan Zhang; Bing Liao; Xiaoyan Xie; Xiaoer Zhang; Guotao Wang; Luyao Zhou
Journal:  Pediatr Surg Int       Date:  2021-05-09       Impact factor: 1.827

5.  Long Noncoding RNA H19 Contributes to Cholangiocyte Proliferation and Cholestatic Liver Fibrosis in Biliary Atresia.

Authors:  Yongtao Xiao; Runping Liu; Xiaojiaoyang Li; Emily C Gurley; Phillip B Hylemon; Ying Lu; Huiping Zhou; Wei Cai
Journal:  Hepatology       Date:  2019-06-21       Impact factor: 17.425

6.  The usefulness of immunohistochemical staining of bile tracts in biliary atresia.

Authors:  Joanna Cielecka-Kuszyk; Maria Janowska; Małgorzata Markiewicz; Piotr Czubkowski; Anna Ostoja-Chyżyńska; Joanna Beata Bierła; Bożena Cukrowska; Joanna Pawłowska
Journal:  Clin Exp Hepatol       Date:  2021-03-25

7.  What Causes Biliary Atresia? Unique Aspects of the Neonatal Immune System Provide Clues to Disease Pathogenesis.

Authors:  Cara L Mack
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2015-05-01

8.  Evolving Up-regulation of Biliary Fibrosis-Related Extracellular Matrix Molecules After Successful Portoenterostomy.

Authors:  Antti Kyrönlahti; Nimish Godbole; Oyediran Akinrinade; Tea Soini; Iiris Nyholm; Noora Andersson; Maria Hukkinen; Jouko Lohi; David B Wilson; Marjut Pihlajoki; Mikko P Pakarinen; Markku Heikinheimo
Journal:  Hepatol Commun       Date:  2021-02-09

9.  Development and Validation of a Novel Fibrosis Marker in Biliary Atresia during Infancy.

Authors:  Hirofumi Tomita; Yasushi Fuchimoto; Akihiro Fujino; Ken Hoshino; Yohei Yamada; Yohei Masugi; Michiie Sakamoto; Mureo Kasahara; Yutaka Kanamori; Atsuko Nakazawa; Fumiko Yoshida; Seiya Akatsuka; Miwako Nakano; Tatsuo Kuroda
Journal:  Clin Transl Gastroenterol       Date:  2015-11-19       Impact factor: 4.488

10.  Increased MMP-7 expression in biliary epithelium and serum underpins native liver fibrosis after successful portoenterostomy in biliary atresia.

Authors:  Anna Kerola; Hanna Lampela; Jouko Lohi; Päivi Heikkilä; Annika Mutanen; Jaana Hagström; Taina Tervahartiala; Timo Sorsa; Caj Haglund; Hannu Jalanko; Mikko P Pakarinen
Journal:  J Pathol Clin Res       Date:  2016-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.